Repligen Appoints Carrie Eglinton Manner to Board of Directors
June 15 2020 - 7:30AM
Repligen Corporation (NASDAQ:RGEN) today announced the appointment
of healthcare industry executive Carrie Eglinton Manner to its
Board of Directors. Ms. Eglinton Manner brings to the director role
over 23 years of leadership experience across multiple disciplines.
She currently serves as Senior Vice President, Advanced Diagnostics
at Quest Diagnostics (NYSE:DGX), the world’s leading provider of
diagnostic information services, which she joined in 2017. Prior to
Quest, Ms. Eglinton Manner held various roles of increasing scope
and responsibility over a period of 20 years at GE Healthcare
(NYSE:GE). From 2009 through 2016, she served as President &
CEO of four distinct GE Healthcare global businesses in the areas
of diagnostic imaging, lab services and medical devices, ranging in
size from approximately $150 million to $3 billion in revenue.
“We are truly pleased to welcome Carrie as a director to our
Board,” said Karen A. Dawes, Chairperson of the Board of Directors
for Repligen. “Her industry knowledge, leadership, and strategic
business acumen will be of great value to the Company and its plans
for continued success. Carrie has a proven track record of building
businesses and leading rapidly growing companies. She is an ideal
addition to our Board.”
Tony J. Hunt, President and Chief Executive Officer said,
“Carrie’s leadership skills are supported by a depth of
disciplinary experience, from early sales and marketing roles at GE
Healthcare to divisional GM and CEO roles entailing acquisition
integration, global market creation, operations excellence, quality
and process improvement. Her history of delivering on business
expansion and profitability will be valuable as we continue to
execute on our innovation-based growth strategy.”
In her role at Quest Diagnostics, Ms. Eglinton Manner is
responsible for growing the company’s nearly $2 billion genetic and
molecular diagnostics portfolio. Under her leadership, the
advanced diagnostics portfolio has grown revenue and margin through
innovation in specialty genetic offerings and services,
productivity programs, key strategic alliances, and acquisitions.
At GE Healthcare, Ms. Eglinton Manner also led improvements in
financial performance and expanded the industry presence as
President and CEO of Maternal Infant Care, Clarient Diagnostic
Services, Inc., Surgery, and Detection & Guidance Solutions. In
addition to joining the Repligen board, Ms. Eglinton Manner serves
as board director for the not-for-profit Thrive Networks, where she
retains a personal and professional commitment to advancing women
and transforming health in underserved communities with reliable
sanitation, water, and education. Ms. Eglinton Manner holds a
Bachelor of Science degree in Mechanical Engineering from the
University of Notre Dame.
About Repligen CorporationRepligen Corporation
is a global life sciences company that develops and commercializes
highly innovative bioprocessing technologies and systems that
increase efficiencies in the process of manufacturing biological
drugs. We are inspiring advances in bioprocessing for the customers
we serve; primarily biopharmaceutical drug developers and contract
development and manufacturing organizations (CDMOs) worldwide. Our
corporate headquarters are located in Waltham, MA (USA), and we
have additional administrative and manufacturing operations in
Marlborough, MA; Bridgewater, NJ; Rancho Dominguez, CA; Lund,
Sweden; Breda, The Netherlands and Ravensburg, Germany.
This press release may contain forward-looking statements within
the meaning of the federal securities laws. Investors are cautioned
that statements in this press release which are not strictly
historical statements including, without limitation, statements
identified by words like “believe,” “expect,” “may,” “will,”
“should,” “seek,” or “could” and similar expressions, constitute
forward-looking statements. Such forward-looking statements are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from those anticipated,
including risks discussed from time to time in our filings with the
Securities and Exchange Commission. We expressly disclaim any
responsibility to update any forward-looking statements, except as
required by law.
Repligen Contact: Sondra S. NewmanGlobal
Head of Investor Relations(781)
419-1881investors@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024